Apogee Therapeutics

APGE

Market cap $5.52B

The chief medical officer at Apogee Therapeutics sold 18,700 shares of the biotech for about $1.46 million. This sale represented 8.09% of Dambkowski's direct holdings, reducing his direct stake, as reported, from 231,223 to 212,523 shares.

10,900 shares directly sold for a total transaction value of $817,500 on Dec. 4, 2025. The transaction represented 3.87% of CMO Carl Dambkowski's direct holdings, reducing direct ownership from 282,008 to 271,108 shares.

Apogee Therapeutics, Inc. (APGE) Discusses Interim Phase Ib Results of Zumilokibart for Mild-to-Moderate Asthma and Pipeline Developments Transcript

Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up  - Results reinforce continued development in asthma testing every 3- or 6-month dosing

SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest inflammatory and immunology (I&I) markets, today announced it will report interim results from its Phase 1b trial of APG777 in patients with mild-to-moderate asthma on Tuesday, January 6, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.

Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Here is how Apogee Therapeutics Inc. (APGE) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing

SAN FRANCISCO and BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences. Guggenheim 2 nd Annual Healthcare Innovation Conference  Date: Tuesday, November 11, 2025Fireside Chat Time: 1:30 p.m.